135 related articles for article (PubMed ID: 38528459)
21. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China's top 3 hospital, 2009-2019.
Liu Y; Ang Q; Wu H; Xu J; Chen D; Zhao H; Liu H; Guo X; Gu Y; Qiu H
Virol J; 2020 Jul; 17(1):104. PubMed ID: 32660490
[TBL] [Abstract][Full Text] [Related]
22. [Use of human papilloma virus testing in primary cervical cancer screening in rural Madagascar].
Dumont A; Bessières N; Razafindrafara G; Ravit M; Benbassa A
Rev Epidemiol Sante Publique; 2019 Apr; 67(2):120-125. PubMed ID: 30448093
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
[TBL] [Abstract][Full Text] [Related]
24. Facilitators and Barriers to HPV Self-Sampling as a Cervical Cancer Screening Option among Women Living with HIV in Rural Uganda.
Nyabigambo A; Mayega RW; Hlongwana K; Ginindza TG
Int J Environ Res Public Health; 2023 May; 20(11):. PubMed ID: 37297609
[No Abstract] [Full Text] [Related]
25. Knowledge, attitudes, and practices of cervical Cancer screening among HIV-positive and HIV-negative women participating in human papillomavirus screening in rural Zimbabwe.
Fitzpatrick M; Pathipati MP; McCarty K; Rosenthal A; Katzenstein D; Chirenje ZM; Pinsky B
BMC Womens Health; 2020 Jul; 20(1):153. PubMed ID: 32711530
[TBL] [Abstract][Full Text] [Related]
26. Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program.
Rosário A; Sousa A; Marinho-Dias J; Medeiros R; Lobo C; Leça L; Coimbra N; Tavares F; Baldaque I; Martins G; Monteiro P; Henrique R; Sousa H
J Med Virol; 2023 Jan; 95(1):e28414. PubMed ID: 36541747
[TBL] [Abstract][Full Text] [Related]
27. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial.
Moses E; Pedersen HN; Mitchell SM; Sekikubo M; Mwesigwa D; Singer J; Biryabarema C; Byamugisha JK; Money DM; Ogilvie GS
Trop Med Int Health; 2015 Oct; 20(10):1355-67. PubMed ID: 26031572
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
29. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology.
Ali MAM; Bedair RN; Abd El Atti RM
Cancer Cytopathol; 2019 Sep; 127(9):567-577. PubMed ID: 31390155
[TBL] [Abstract][Full Text] [Related]
30. High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program.
Torres-Poveda K; Ruiz-Fraga I; Madrid-Marina V; Chavez M; Richardson V
BMC Cancer; 2019 Dec; 19(1):1205. PubMed ID: 31823749
[TBL] [Abstract][Full Text] [Related]
31. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
32. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
Rebolj M; Cuschieri K; Mathews CS; Pesola F; Denton K; Kitchener H;
BMJ; 2022 May; 377():e068776. PubMed ID: 35640960
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
34. Uptake and correlates of cervical cancer screening among women attending a community-based multi-disease health campaign in Kenya.
Choi Y; Ibrahim S; Park LP; Cohen CR; Bukusi EA; Huchko MJ
BMC Womens Health; 2022 Apr; 22(1):122. PubMed ID: 35436908
[TBL] [Abstract][Full Text] [Related]
35. Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection.
Rodriguez NM; Brennan LP; Claure L; Balian LN; Champion VL; Forman MR
PLoS One; 2023; 18(3):e0282853. PubMed ID: 36893182
[TBL] [Abstract][Full Text] [Related]
36. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and genotype screening of human papillomavirus among women attending a private hospital in Northern Cyprus: an 11-year retrospective study.
Baddal B; Oktay MN; Bostanci A; Yenen MC
BMC Womens Health; 2023 Jun; 23(1):297. PubMed ID: 37270608
[TBL] [Abstract][Full Text] [Related]
38. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
[No Abstract] [Full Text] [Related]
39. Prevalence and Distribution of Vaccine-Preventable Genital Human Papillomavirus(HPV) Genotypes in Ghanaian Women Presenting for Screening.
Donkoh ET; Asmah RH; Agyemang-Yeboah F; Dabo EO; Wiredu EK
Cancer Control; 2022; 29():10732748221094721. PubMed ID: 35536890
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with uptake of human papilloma virus vaccine among school girls aged 9-14 years in Lira City northern Uganda: a cross-sectional study.
Nakayita RM; Benyumiza D; Nekesa C; Misuk I; Kyeswa J; Nalubuuka A; Murungi T; Udho S; Kumakech E
BMC Womens Health; 2023 Jul; 23(1):362. PubMed ID: 37420225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
